Last 1,594
Change Today 0.00 / 0.00%
Volume 0.0
KMDA On Other Exchanges
Tel Aviv
As of 10:24 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/14 - $6,200
52 Week Low
11/25/14 - $1,160
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. Its respiratory disease products, including Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-1 antitrypsin deficiency; and Bramitob to manage chronic pulmonary infection. The company’s immunoglobulin products include KamRAB for prophylaxis against rabies infection; KamRho(D)IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; Snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. In addition, it provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of proper level in the patient’s blood plasma. Further, the company offers Heparin Lock Flush to maintain patency of indwelling IV catheter; Human Transferrin for diagnostic assays and cell cultures; and Kamacaine 0.5% used as anesthesia or analgesia for surgery, obstetrical procedures, and diagnostic and therapeutic procedures, as well as spinal anesthesia for surgery. Additionally, it offers coagulation factors, including Factor VIII, Factor IX, and Bupivacaine. The company also develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary disease, graft-versus-host diseases, and transplantations. It has a collaboration partnership with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States and Europe; and distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

289 Employees
Last Reported Date: 03/26/14
Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $1.5M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $232.0K
Vice President of Clinical Development & IP
Total Annual Compensation: $177.0K
Vice President of Research and Development
Total Annual Compensation: $199.0K
Compensation as of Fiscal Year 2013.

kamada ltd (KMDA) Key Developments

Kamada Ltd.(TASE:KMDA) dropped from TA-100 Index

Kamada Ltd. will be removed from the TA-100 Index.

Kamada Ltd. Reports Interim Data from A Phase I/II Clinical Study of Proprietary Human Alpha-1 Antitrypsin

Kamada Ltd. reported that interim data from a Phase I/II clinical study of the company's proprietary human Alpha-1 Antitrypsin (AAT) conducted by the Fred Hutchinson Cancer Research Center in Seattle, Washington, for the treatment of graft-versus-host-disease (GvHD) were highlighted in a poster presentation at the 56th American Society of Hematology Annual Meeting and Exposition being held from December 5-9, 2014 in San Francisco. Interim results from the Phase I/II study were presented in a poster entitled Alpha 1 Anti-Trypsin (AAT) offers potent therapy for Steroid Resistant Gut GvHD: Interim Results of a Phase I/II Clinical Study, December 8, 2014 by A. Mario Marcondes M.D. Ph.D, Clinical Research Associate at the Fred Hutchinson Cancer Research Center, Research Assistant Professor at the University of Washington and an investigator of the clinical study. GvHD is a major complication of allogeneic hematopoietic cell transplantation (HCT). Severe acute GvHD can be life threatening and it is associated with a loss of proteins including AAT. The Phase I/II study is being conducted by the Fred Hutchinson Cancer Research Center in Seattle, Washington in cooperation with Baxter International Inc. and Kamada using Kamada's AAT. The is an open label, dose escalation, safety and efficacy study. The study is evaluating 24 GvHD patients who suffer from inadequate response to steroid treatment following HCT. The patients are enrolled into 4 dose cohorts. The primary outcome of the study is to evaluate the efficacy of AAT in ameliorating the severe intestinal inflammation associated with GvHD. To date, 7 patients with hematologic malignancies were enrolled, 6 of which were enrolled in the first cohort. Patients showing no clinically satisfactory responses to steriods were given AAT at 90 mg/kg IV on day 1, followed by 30 mg/kg (first cohort) every other day for a total of 8 doses (15 days). Preliminary results indicated that continuous administration of AAT as therapy for steroid resistant gut GvHD is feasible in the subject population. Indication of healing of the bowel mucosa was seen to decrease in diarrhea, in intestinal protein loss, including AAT, and in endoscopic evaluation. Additionally, following examination of pro-inflammatory cytokines, in the preliminary results AAT administration suppressed serum levels of pro-inflammatory cytokines and interfered with GvHD biomarkers.

Kamada Ltd. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 08:00 AM

Kamada Ltd. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 08:00 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,594.00 0.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €37.25 EUR +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at